Advertisement
Journal Home
Search for

Volume 199, Issue 6, Supplement B, Pages S328-S332 (December 2008)


View previous. 9 of 18 View next.

The clinical content of preconception care: women with psychiatric conditions

Ariela Frieder, MDaCorresponding Author Informationemail address, Anne L. Dunlop, MD, MPHb, Larry Culpepper, MD, MPHc, Peter S. Bernstein, MD, MPHd

Received 17 June 2008; received in revised form 29 August 2008; accepted 3 September 2008.

For a substantial proportion of women, pregnancy can be complicated by the occurrence or reoccurrence of a psychiatric condition. Psychiatric disorders during pregnancy are associated with poor obstetric outcomes, higher risk of postpartum psychiatric illness, increased rates of substance abuse, lower participation in prenatal care, and adverse infant and family outcomes. As part of preconception care, providers should be vigilant and screen for psychiatric disorders among women of reproductive age, as the detection and appropriate management of these conditions can reduce the occurrence of adverse pregnancy and family outcomes. This manuscript reviews the treatment options and the risks and benefits of discontinuing, changing, or continuing psychotropic medications for women of reproductive age with common psychiatric disorders (depression and anxiety disorders, bipolar disorder, and schizophrenia) and offers recommendations for preconception care.

a Department of Psychiatry, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

b Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA

c Department of Family Medicine, Boston University School of Medicine, Boston, MA

d Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

Corresponding Author InformationReprints: Ariela Frieder, MD, Department of Psychiatry and Behavioral Sciences, Montefiore Medical Center, 111 East 210th St., Bronx, NY 10467

 Conflict of Interest: Ariela Frieder, MD; Anne L. Dunlop, MD, MPH; and Peter S. Bernstein, MD, MPH have no conflict of interest including grants, honoraria, advisory board membership, or share holdings. Larry Culpepper, MD, MPH is a consultant or is on the advisory board of Forest Labs, New York, NY; Pfizer, New York, NY; Wyeth, Madison, NJ; AstraZeneca, Wilmington, DE; Lilly, Indianapolis, IN; and Cephalon, Frazer, PA. He is on a Speakers Bureau for Forest Labs, Pfizer, and Wyeth.

PII: S0002-9378(08)01039-9

doi:10.1016/j.ajog.2008.09.001


View previous. 9 of 18 View next.

Advertisement